Leap-In Transposase
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Wheeler Bio
PAO-06-24-CL-05May 30, 2024
CMC
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.
Wheeler Bio
PAO-07-23-CL-05Jul 26, 2023
Cell Line Development Technology
Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering
Wheeler Bio
PR-M11-22-09Nov 30, 2022
Series A Funding
Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma
Wheeler Bio
PR-M10-22-02Oct 05, 2022